Testing effectiveness (Phase 2)UnknownNCT02599064
What this trial is testing
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
Who this might be right for
Age-related Macular DegenerationSubfoveal Choroidal NeovascularizationSubretinal Scarring+1 more
RXi Pharmaceuticals, Corp. 9